Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and ...

Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, its strong top-line performance caught investor attention. Amgen’s total ...

Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the ...